Business
Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California
QUÉBEC CITY, Dec. 5, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: ...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, Dec. 5, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the \"Company\") today announced the following\n presentations on perifosine, its novel, oral anticancer Akt inhibitor,\n at the upcoming American Society of Hematology (ASH) Annual Meeting and\n Exposition, which will be held December 10 -13, 2011, at the San Diego\n Convention Center in San Diego, California:\n\n\n\n\n\nAbstract #815: \n\n\n\"Perifosine Plus Bortezomib and Dexamethasone in Relapsed/ Refractory\n Multiple Myeloma Patients Previously Treated with Bortezomib & nbsp;\n Final Results of a Phase 1/2 Trial\"\n\n\n \n\n\nP.G. Richardson, J.L. Wolf, A.J. Jakubowiak, J.A. Zonder, S. Lonial, D.\n Irwin, J. Densmore, A. Krishnan, N.S. Raje, M.H. Bar, R. Schlossman,\n I.M. Ghobrial, N.C. Munshi, T. Martin, J.P. Laubach, J.P Allerton, T.\n Hideshima, P. Sportelli, L. Gardner, and K.C. Anderson\n\n\n \n\n\n(oral presentation)\n\n\nPresenter: \n\n\nPaul Richardson, MD, Clinical Director of the Jerome Lipper Multiple\n Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.\n\n\nSession 653: \n\n\nMyeloma - Therapy, Excluding Transplantation: Novel Drugs in\n Relapsed/Refractory Myeloma Patients \n\n\nDate and time: \n\n\nMonday, December 12, 2011, at 5:30 p.m. (Pacific)\n\n\nVenue: \n\n\nBallroom 20D, San Diego Convention Center\n\n\n \n\n\n \n\n\nAbstract #1653: \n\n\n\"Preclinical Rationale for the Use of Combined Treatment with the Akt\n Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin\n Lymphoma\",  Locatelli S.L., Giacomini A., Guidetti A., Cleris L., Magni M., Di\n Nicola M., Mortarini R., Gianni A.M., Anichini A., Carlo-Stella C.\n\n\nPresenter:  \n\n\nSilvia Locatelli, PhD, Fondazione IRCCS Instituto Nazionale Tumori, Milan, Italy\n\n\nSession 625:  \n\n\nLymphoma - Pre-Clinical - Chemotherapy and Biologic Agents: Poster I\n\n\nDate and time: \n\n\nSaturday, December 10, 2011, 5:30 p.m. - 7:30 p.m. (Pacific)\n\n\nVenue: \n\n\nHall GH, San Diego Convention Center\n\n\n \n\n\n \n\n\nAbstract #3705:\n\n\n \"Phosphorylation Levels of Extracellular-Signal Regulated Kinase (Erk)\n and Akt in Circulating Lymphocytes Predict Response to Targeted Therapy\n with Kinase Inhibitors...